Based on the Likert scale, most patients with atopic dermatitis (AD) using baricitinib reported being either “satisfied” (76%) or “very satisfied” (18%). Most patients with atopic dermatitis (AD) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback